Océane Landon-Cardinal

Océane Landon-Cardinal

Auto-generated profile, based on publicly available information

Océane Landon-Cardinal

Division of Rheumatology, Centre hospitalier de l’Université de Montréal (CHUM), Montreal, Quebec, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2018 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
OLOcéane Landon-Cardinal
Océane Landon-Cardinal
YAYves Allenbach
Yves Allenbach
ASAntoine Soulages
Antoine Soulages
ARAude Rigolet
Aude Rigolet
BHBaptiste Hervier
Baptiste Hervier
OBOlivier Benveniste
Olivier Benveniste
Objective.: A pathogenic role of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibodies has been proposed. Our objective was to assess efficacy of rituximab (RTX) in anti-HMGCR immune-mediated necrotizing myopathy.Methods.: All patients who had been treated with RTX were retrospectively reviewed to assess features and outcome.Results.: Three of 9 patients demonstrated stable or improved muscle strength ± decline in creatine kinase levels, or T2/short-tau inversion recovery hypersignal decrease on magnetic resonance imaging following RTX treatment. RTX permitted intravenous immunoglobulin discontinuation and corticosteroid reduction to low dose in 2 patients.Conclusion.: One-third of patients with refractory anti-HMGCR had improved strength or other evidence of improved disease activity following RTX treatment.

29 May 2018 in Journal of Neuromuscular Diseases
Verified
Journal Article
Closed access
PDF file
OLOcéane Landon-Cardinal
Océane Landon-Cardinal
DFDiane Friedman
Diane Friedman
MGMarguerite Guiguet
Marguerite Guiguet
PLPascal Laforêt
Pascal Laforêt
NHNicholas Heming
Nicholas Heming
OBOlivier Benveniste
Olivier Benveniste
Background: Several retrospective case series have suggested rituximab (RTX) might improve patients with refractory Myasthenia Gravis (MG). Objective: In this study, we aimed to evaluate prospectively the efficacy of RTX on muscle function in refractory generalized anti-acetylcholine receptor (AChR) MG patients. Methods: Enrolled patients received 1 g of RTX at day 0, day 14, and 6-month follow-up (M6). The primary endpoint was improvement of muscle function at 12-month (M12) based on myasthenic muscle score (MMS). Secondary endpoints were an improvement of the MG Foundation of America Postintervention Status (MGFA-PIS), respiratory forced vital capacity, occurrences of acute MG exacerbation and requirement of associated immunosuppressants and immunomodulatory agents. Results: Twelve patients were enrolled, and 11 completed the study. Only a single patient presented an improvement of at least 20 points on MMS at M12, although 2 patients displayed an increase of at least 18 points at M12. MGFA-PIS had improved in 55% of patients by M12. The clinical improvement was not associated with a reduction of immunosuppressant burden. Conclusions: These results provide data on the effect of RTX in patients with severe, refractory anti-AChR Abs generalized MG. Even though primary outcome was only reached in a single patient at M12, a beneficial effect of RTX on muscle function was seen in half of the patients at M12 and persisted in a third of patients at M18.

1 December 2020 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
OLOcéane Landon-Cardinal
Océane Landon-Cardinal
CKCédi Koumako
Cédi Koumako
GHGiulia Hardouin
Giulia Hardouin
BGBenjamin Granger
Benjamin Granger
HRHarmen Reyngoudt
Harmen Reyngoudt
YAYves Allenbach
Yves Allenbach

1 July 2021 in Autoimmunity Reviews
Verified
Journal Article
Closed access
FLFrédéric Lefebvre
Frédéric Lefebvre
MGMargherita Giannini
Margherita Giannini
BEBenjamin Ellezam
Benjamin Ellezam
VLValérie Leclair
Valérie Leclair
YTYves Troyanov
Yves Troyanov
OLOcéane Landon-Cardinal
Océane Landon-Cardinal

5 September 2020 in RMD Open
Verified
Journal Article
Open access
PDF file
OLOcéane Landon-Cardinal
Océane Landon-Cardinal
ABAlexandra Baril-Dionne
Alexandra Baril-Dionne
SHSabrina Hoa
Sabrina Hoa
AMAlain Meyer
Alain Meyer
VLValérie Leclair
Valérie Leclair
JSJean-Luc Senécal
Jean-Luc Senécal
Objective To describe systemic sclerosis (SSc) with myopathy in patients without classic SSc-specific and SSc-overlap autoantibodies (aAbs), referred to as seronegative scleromyositis. Methods Twenty patients with seronegative scleromyositis diagnosed by expert opinion were analysed retrospectively for SSc features at myositis diagnosis and follow-up, and stratified based on HEp-2 nuclear patterns by indirect immunofluorescence (IIF) according to International Consensus of Autoantibody Patterns. Specificities were analysed by protein A−assisted immunoprecipitation. Myopathy was considered an organ involvement of SSc. Results SSc sine scleroderma was a frequent presentation (45%) at myositis diagnosis. Myositis was the most common first non-Raynaud manifestation of SSc (55%). Lower oesophagal dysmotility was present in 10 of 11 (91%) investigated patients. At follow-up, 80% of the patients met the American College of Rheumatology/EULAR SSc classification criteria. Two-thirds of patients had a positive HEp-2 IIF nuclear pattern (all with titers ≥1/320), defining three novel scleromyositis subsets. First, antinuclear antibody (ANA)-negative scleromyositis was associated with interstitial lung disease (ILD) and renal crisis. Second, a speckled pattern uncovered multiple rare SSc-specific aAbs. Third, the nuclear dots pattern was associated with aAbs to survival of motor neuron (SMN) complex and a novel scleromyositis subset characteriszed by calcinosis but infrequent ILD and renal crisis. Conclusions SSc skin involvement is often absent in early seronegative scleromyositis. ANA positivity, Raynaud phenomenon, SSc-type capillaroscopy and/or lower oesophagal dysmotility may be clues for scleromyositis. Using HEp-2 IIF patterns, three novel clinicoserological subsets of scleromyositis emerged, notably (1) ANA-negative, (2) ANA-positive with a speckled pattern and (3) ANA-positive with nuclear dots and anti-SMN aAbs.

12 August 2022 in Neuropathology and Applied Neurobiology
Verified
Journal Article
Closed access
BEBenjamin Ellezam
Benjamin Ellezam
VLValérie Leclair
Valérie Leclair
YTYves Troyanov
Yves Troyanov
IBImane Bersali
Imane Bersali
MGMargherita Giannini
Margherita Giannini
OLOcéane Landon‐Cardinal
Océane Landon‐Cardinal